Glenmark Generics Ltd enhances Pain Management Portfolio for the U.S Market

Date: 10 November 2008

Glenmark Generics Ltd’s US subsidiary(GGI) has initiated distribution of Morphine Sulfate Oral Concentrate Solution in the U.S. market through a licensing agreement with a U.S. based pharmaceutical development company.  This will be the fifth product offered by Glenmark in the category of pain management. 

Morphine Sulfate Oral Concentrate Solution 20mg/ml is offered in three presentations and is indicated for the relief of moderate to severe pain. Total sales for the 12 month period ending June 2008 were in excess of USD 15 million as stated by IMS Health. 

This product launch complements Glenmark’s presently established portfolio of both oral solid and oral liquid pain management products. This niche market category maintains a high barrier to entry due to strict DEA regulations thereby limiting the number of competitor companies and showcasing Glenmark as the sole India-based company in each of their product launches. These products are manufactured for Glenmark in the United States through a partnership and are distributed directly from GGI’s 75,000 square ft warehouse located in Mahwah, New Jersey. 

Glenmark’s current portfolio consists of 36 products authorized for distribution in the U.S. marketplace.  The Company has 40 ANDA’s in various stages of the approval process with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.  

About Glenmark Generics Ltd. (GGL) Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America. The Company has a state-of-the-art manufacturing plant at Goa, India that is approved by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 30 USDMFs filed and/or approved along with several Canadian DMFs, EDMFs and CEPs/CoSs. [www.glenmark-generics.com]  

About Glenmark Pharmaceuticals Ltd:Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Its shares are listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). It employs over 5500 people across its global operations over 85 countries. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.], and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark’s first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211 has been out-licensed to Eli Lilly & company. For more information on GPL, log on to http://www.glenmarkpharma.com/ 

For further information, please contact: 

Jason D’Souza | Medha Satam

Glenmark, Mumbai, India Tel: [+91 22] 40189919 / 40189993 Email :  connect@glenmark-generics.com               

Download PDF